Los Angeles Capital Management’s ALX Oncology ALXO Stock Holding History

Los Angeles Capital Management’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-409,938	Closed	-$255K	–	1327
2025 Q1	$255K	Buy	409,938 +108,519	+36%	+$130K	﹤0.01%	944
2024 Q4	$503K	Buy	301,419 +43,640	+17%	+$67.1K	﹤0.01%	812
2024 Q3	$469K	Buy	+257,779	New	+$958K	﹤0.01%	878
2024 Q2	–	Sell	-98,960	Closed	-$1.1M	–	1168
2024 Q1	$1.1M	Sell	98,960 -24,460	-20%	-$344K	﹤0.01%	666
2023 Q4	$1.84M	Sell	123,420 -23,257	-16%	-$221K	0.01%	498
2023 Q3	$704K	Hold	146,677	–	–	﹤0.01%	748
2023 Q2	$1.1M	Buy	146,677 +3,170	+2%	+$20.8K	﹤0.01%	631
2023 Q1	$649K	Sell	143,507 -6,425	-4%	-$48.7K	﹤0.01%	781
2022 Q4	$1.69M	Sell	149,932 -1,180	-0.8%	-$13.3K	0.01%	557
2022 Q3	$1.45M	Buy	151,112 +52,148	+53%	+$608K	0.01%	588
2022 Q2	$801K	Buy	+98,964	New	+$1.08M	﹤0.01%	800
2021 Q4	–	Sell	-3,979	Closed	-$294K	–	1385
2021 Q3	$294K	Buy	+3,979	New	+$265K	﹤0.01%	1316

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Los Angeles Capital Management's ALXO Position: Q2 2025 in Review

Los Angeles Capital Management sold out of ALX Oncology (ALXO) in Q2 2025, closing a stake of 409,938 shares — an estimated $255K sold.

Los Angeles Capital Management first reported a position in ALXO in Q3 2021 and held it in 12 quarters. The position peaked at $1.84M in Q4 2023. 61 funds tracked by Wall St. Rank hold ALXO as of Q2 2025.

Los Angeles Capital Management reported no remaining ALX Oncology position as of Q2 2025 after selling out during the quarter.
Los Angeles Capital Management sold 409,938 ALX Oncology shares in Q2 2025, an estimated $255K.
Los Angeles Capital Management first reported a position in ALX Oncology in Q3 2021 and held it in 12 quarters.
Los Angeles Capital Management's ALX Oncology position peaked at $1.84M in Q4 2023.
61 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2025.

Based on Los Angeles Capital Management's 13F filing for Q2 2025, filed 7 Aug 2025.